Aktuellt
SENASTE
Redeye comments on Fluoguide posting interim data from its phase IIa trial with FG001 in NSCLC (FG001-CT002). FG001-CT002 interim data from the first eight patients aligned with our expectations, showing good tolerability and cancer tissue lighting up in most patients. We leave our estimates unchanged but view the communicated data as an incremental positive.
LÄS MER
